Docetaxel
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1995
- First approval year
- 1995
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Docetaxel
- Molecular weight
- 861.94
- Structure (SMILES)
- CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
- beizray
- Beizray
- docetaxel
- Docetaxel
- docetaxel accord
- Docetaxel accord
- docetaxel teva
- Docetaxel teva
- Docetaxel zentiva (previously docetaxel winthrop)
- docetaxel zentiva previously docetaxel winthrop
- docivyx
- Docivyx
- taxceus
- Taxceus
- Taxespira (previously docetaxel hospira uk limited )
- taxespira previously docetaxel hospira uk limited
- taxotere
- Taxotere
- (2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate
- 2r 3s n carboxy 3 phenylisoserine n tert butyl ester 13 ester with 5β 20 epoxy 1 2α 4 7β 10β 13α hexahydroxytax 11 en 9 one 4 acetate 2 benzoate trihydrate
- abt 348 and docetaxel
- BH009 (Docetaxel injection)
- docetaxel
- Docetaxel
- DOCETAXEL
- Docetaxel (as trihydrate)
- Docetaxel (DOC)
- Docetaxel (post-operative)
- docetaxel (T)
- Docetaxel (T)
- Docetaxel (Taxane)
- Docetaxel (Taxotere)
- docetaxel (Taxotere®)
- Docetaxel (Taxotere®)
- docetaxel (XRP6976)
- Docetaxel (XRP6976)
- DOCETAXEL (XRP6976)
- DOCETAXEL [EMA EPAR]
- DOCETAXEL [EP MONOGRAPH]
- DOCETAXEL [ORANGE BOOK]
- DOCETAXEL [USAN]
- DOCETAXEL [USP IMPURITY]
- DOCETAXEL [USP MONOGRAPH]
And 44 more, listed on the interactive page.
- ATC classification codes
- L01CD02
Sources for recorded values
- ChEMBL ID
- CHEMBL3545252
- InChIKey
- XCDIRYDKECHIPE-QHEQPUDQSA-N
- PubChem compound IDs
- 148123
- RxNorm IDs (RxCUI)
- 72962
- FDA ingredient codes (UNII)
- 15H5577CQD
- 114977-28-5
- 148408-66-6
- Applicant
- SANOFI AVENTIS US
- Approval date
- 14 May 1996
- Application number
- NDA020449
- Status
- Authorised
- Status date
- 27 Nov 1995
- Authorisation date
- 27 Nov 1995
- Approved indications
- Breast cancer Taxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: operable node-positive breast cancer; operable node-negative breast cancer. For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Non-small-cell lung cancer Taxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy. Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition. Prostate cancer Taxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Gastric adenocarcinoma Taxotere in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. Head and neck cancer Taxotere in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
- Product number
- EMEA/H/C/000073
- Authorisation holder
- Sanofi Winthrop Industrie
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 2
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Adenocarcinoma
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Head and Neck Neoplasms
- Prostatic Neoplasms
- Stomach Neoplasms
European medicines record
- Patents
- 8
- Designations
- 2
- Earliest recorded loss of exclusivity
- 16 May 2036
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- Yes
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- docetaxel
- Type
- Synthetic organic
- Drug name stem
- -taxel
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- tubulin beta class I
- Gene symbol
- TUBB
- Protein identifier
- P07437
- Primary target
- Yes
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P04350
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P07437
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P0DPH7
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68363
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68366
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68371
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q13509
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q13885
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q3ZCM7
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q6PEY2
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q71U36
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BQE3
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BUF5
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BVA1
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9H4B7
Open Targets mechanisms
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Action type
- Inhibitor
- Gene symbol
- EGFR
- Protein identifier
- P00533
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8
- Protein identifier
- P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Sarcoma, Ewing
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000174
- Subject identifier
- D012512
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Adenocarcinoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000228
- Subject identifier
- D000230
- Condition
- Breast Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Carcinoma, Intraductal, Noninfiltrating
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000432
- Subject identifier
- D002285
- Condition
- Carcinoma, Endometrioid
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000466
- Subject identifier
- D018269
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Leiomyosarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000564
- Subject identifier
- D007890
- Condition
- Leukemia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Adenocarcinoma of Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000571
- Subject identifier
- D000077192
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Osteosarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000637
- Subject identifier
- D012516
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Sarcoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000707
- Subject identifier
- D002294
And 95 more, listed on the interactive page.
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000196
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000199
- Condition identifier
- EFO_0000228
- Condition identifier
- EFO_0000305
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000432
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000564
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000637
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000707
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000708
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001075
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001376
- Condition identifier
- EFO_0001416
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001663
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Condition identifier
- EFO_0002916
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002938
- Highest recorded phase
- 3
And 268 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- dermatological toxicity
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Warning
- Black Box Warning
- Effect
- respiratory toxicity
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Warning
- Black Box Warning
- Effect
- dermatological toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- respiratory toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Country
- United States
- Event
- alopecia
- Reports
- 642
- Reporting signal score
- 384.895
- Event
- anaemia
- Reports
- 2,990
- Reporting signal score
- 1,620.56
- Event
- bone marrow failure
- Reports
- 778
- Reporting signal score
- 806.103
- Event
- dehydration
- Reports
- 1,655
- Reporting signal score
- 849.951
- Event
- diarrhoea
- Reports
- 4,761
- Reporting signal score
- 1,375.61
- Event
- disease progression
- Reports
- 1,578
- Reporting signal score
- 1,064.51
- Event
- ejection fraction decreased
- Reports
- 316
- Reporting signal score
- 430.654
- Event
- febrile neutropenia
- Reports
- 2,863
- Reporting signal score
- 3,948.54
- Event
- flushing
- Reports
- 1,152
- Reporting signal score
- 752.625
- Event
- leukopenia
- Reports
- 1,467
- Reporting signal score
- 1,336.2
- Event
- malignant neoplasm progression
- Reports
- 1,767
- Reporting signal score
- 1,906.17
- Event
- metastases to bone
- Reports
- 589
- Reporting signal score
- 876.407
- Event
- metastases to liver
- Reports
- 599
- Reporting signal score
- 910.583
- Event
- metastases to lung
- Reports
- 210
- Reporting signal score
- 354.841
- Event
- metastases to lymph nodes
- Reports
- 192
- Reporting signal score
- 381.465
- Event
- mucosal inflammation
- Reports
- 1,257
- Reporting signal score
- 1,693.18
- Event
- myelosuppression
- Reports
- 841
- Reporting signal score
- 1,534.1
- Event
- nausea
- Reports
- 2,058
- Reporting signal score
- 359.135
- Event
- neuropathy peripheral
- Reports
- 1,955
- Reporting signal score
- 1,627.85
- Event
- neutropenia
- Reports
- 3,615
- Reporting signal score
- 3,317.13
- Event
- neutropenic sepsis
- Reports
- 245
- Reporting signal score
- 482.469
- Event
- neutrophil count decreased
- Reports
- 1,098
- Reporting signal score
- 1,066.88
- Event
- palmar-plantar erythrodysaesthesia syndrome
- Reports
- 944
- Reporting signal score
- 1,187.39
- Event
- peripheral sensory neuropathy
- Reports
- 508
- Reporting signal score
- 884.881
- Event
- pyrexia
- Reports
- 2,995
- Reporting signal score
- 805.212
And 2 more, listed on the interactive page.
- NCT00002544
- NCT00002662
- NCT00002707
- NCT00002901
- NCT00003066
- NCT00003103
- NCT00003352
- NCT00003519
- NCT00003565
- NCT00003679
- NCT00003782
- NCT00003953
- NCT00004125
- NCT00004175
- NCT00004888
- NCT00004906
- NCT00005800
- NCT00005908
- NCT00005963
- NCT00006104
- NCT00006120
- NCT00006261
- NCT00006682
- NCT00008411
- NCT00010140
And 1,424 more, listed on the interactive page.
- Dose
- 75 mg/m2
- Route
- Intravenous
- How often
- Every 3 weeks
- Hydrogen bond acceptors
- 14
- Hydrogen bond donors
- 5
- Polar surface area
- 224.45
- Calculated partition coefficient (ALogP)
- 3.26
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 8
- Heavy atoms
- 61
- Molecular formula
- C43H59NO17
- Monoisotopic mass
- 861.37829941
- Natural product
- No
- 0143-9204
- 0143-9205
- 0409-0365
- 0409-0366
- 0409-0367
- 0409-0368
- 0409-4235
- 0409-5068
- 0955-1020
- 0955-1021
- 0955-1022
- 23155-903
- 23155-904
- 23155-905
- 43066-001
- 43066-006
- 43066-010
- 43598-258
- 43598-259
- 43598-389
- 43598-610
- 43598-611
- 45963-734
- 45963-765
- 66758-050
And 9 more, listed on the interactive page.
- Recorded assays
- 1,468
- Active assays
- 820
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (2,292)
- "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
- 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
- 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
- 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
- 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
- 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
- 6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients
- A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
- A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours
- A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
- A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
- A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
- A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
- A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
Approved for (21)
- Adenocarcinoma
- Breast cancer
- Breast carcinoma
- Breast neoplasm
- Cancer
- Gastric adenocarcinoma
- Gastric cancer
- Gastric carcinoma
- Gastric neoplasm
- Gastroesophageal junction adenocarcinoma
- Head and neck cancer
- Head and neck carcinoma
- Head and neck neoplasm
- Malignant tumor of neck
- Metastatic prostate carcinoma
- Neoplasm
- Non-small cell lung carcinoma
- Prostate adenocarcinoma
- Prostate cancer
- Prostate carcinoma
In development for (94)
- Allergic disease Phase 3
- Biliary tract cancer Phase 2
- Biliary tract neoplasm Phase 2
- Carcinoma Phase 3
- Carcinoma of esophagus Phase 3
- Cervical adenocarcinoma Phase 3
- Cervical cancer Phase 3
- Cervical squamous cell carcinoma Phase 1
- Colonic neoplasm Phase 1
- Colorectal cancer Phase 2
- Ductal breast carcinoma in situ Phase 2
- Endometrial cancer Phase 3
- Endometrial carcinoma Phase 3
- Endometrioid adenocarcinoma Phase 1
- Esophageal cancer Phase 3
- Esophageal squamous cell carcinoma Phase 3
- Ewing sarcoma Phase 2
- Exocrine pancreatic carcinoma Phase 2
- Fallopian tube cancer Phase 3
- Gastrointestinal stromal tumor Phase 2
Other linked conditions (2)
Targets (15)
- TUBA1A Tubulin inhibitor
- TUBA1B Tubulin inhibitor
- TUBA1C Tubulin inhibitor
- TUBA3C Tubulin inhibitor
- TUBA3E Tubulin inhibitor
- TUBA4A Tubulin inhibitor
- TUBB Tubulin inhibitor
- TUBB1 Tubulin inhibitor
- TUBB2A Tubulin inhibitor
- TUBB2B Tubulin inhibitor
- TUBB3 Tubulin inhibitor
- TUBB4A Tubulin inhibitor
- TUBB4B Tubulin inhibitor
- TUBB6 Tubulin inhibitor
- TUBB8 Tubulin inhibitor